View Filing Data

Document and Entity Information - shares	3 Months Ended
Document and Entity Information - shares	Mar. 31, 2016	Apr. 30, 2016
Document and Entity Information
Entity Registrant Name	Innoviva, Inc.
Entity Central Index Key	0001080014
Document Type	10-Q
Document Period End Date	Mar. 31, 2016
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Current Reporting Status	Yes
Entity Filer Category	Large Accelerated Filer
Entity Common Stock, Shares Outstanding		113,069,974
Document Fiscal Year Focus	2016
Document Fiscal Period Focus	Q1

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands

Mar. 31, 2016

Dec. 31, 2015

^[1]

Current assets:

Cash and cash equivalents

$ 151,778

$ 159,180

Short-term marketable securities

16,414

28,103

27,539

26,228

Prepaid expenses and other current assets

975

814

Total current assets

196,706

214,325

Property and equipment, net

193

221

Capitalized fees paid to a related party, net

190,912

194,368

Other assets

Total assets

387,829

408,932

Current liabilities:

Accounts payable

576

818

Accrued personnel-related expenses

913

1,659

Accrued interest payable

6,562

7,911

Other accrued liabilities

1,687

2,218

Deferred revenue

885

Total current liabilities

10,623

13,491

Convertible subordinated notes, due 2023

251,124

250,992

Non-recourse notes, due 2029

483,389

482,139

Other long-term liabilities

1,784

1,856

Deferred revenue

2,878

3,099

Commitments and contingencies (Notes 3, 6 and 9)

Stockholders' deficit:

Preferred stock: $0.01 par value, 230 shares authorized, no shares issued and outstanding

Common stock: $0.01 par value, 200,000 shares authorized, 113,146 and 114,933 shares issued as of March 31, 2016 and December 31, 2015, respectively

1,132

1,149

Treasury stock: 150 shares as of March 31, 2016 and December 31, 2015

(3,263)

Additional paid-in capital

1,328,155

1,351,898

Accumulated other comprehensive loss

(1)

(2)

Accumulated deficit

(1,687,992)

(1,692,427)

Total stockholders' deficit

(361,969)

(342,645)

Total liabilities and stockholders' deficit

$ 387,829

$ 408,932

[1]	Condensed consolidated balance sheet as of December 31, 2015 has been derived from audited consolidated financial statements.

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Mar. 31, 2016	Dec. 31, 2015
CONDENSED CONSOLIDATED BALANCE SHEETS
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized	230,000	230,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized	200,000,000	200,000,000
Common stock, shares issued	113,146,000	114,933,000
Treasury Stock, Shares	150,000	150,000

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Revenue:
Royalty revenue from a related party, net of amortization for capitalized fees paid to a related party of $3,456 for the three months ended March 31, 2016 and 2015	$ 23,955	$ 6,674
Revenue from collaborative arrangements from a related party, net	221	222
Total net revenue	24,176	6,896
Operating expenses:
Research and development	392	712
General and administrative	6,252	5,439
Total operating expenses	6,644	6,151
Income from operations	17,532	745
Other income (expense), net	(32)	1,178
Interest income	92	116
Interest expense	(13,157)	(12,706)
Net income (loss)	$ 4,435	$ (10,667)
Basic and diluted net income (loss) per share	$ 0.04	$ (0.09)
Shares used to compute basic and diluted net income (loss) per share:
Shares used to compute basic net income (loss) per share	112,482	114,658
Shares used to compute diluted net income (loss) per share	113,178	114,658
Cash dividend declared per common share (in dollars per share)	$ 0	$ 0.25

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
Amortization of capitalized fees paid to a related party	$ 3,456	$ 3,456

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)
Net income (loss)	$ 4,435	$ (10,667)
Other comprehensive income:
Unrealized gain on marketable securities, net	1	1,226
Less: Realized gain on marketable securities, net	0	(1,151)
Comprehensive income (loss)	$ 4,436	$ (10,592)

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References + Details

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
$ in Thousands

3 Months Ended

Mar. 31, 2016

Mar. 31, 2015

Cash flows from operating activities

Net income (loss)

$ 4,435

$ (10,667)

Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:

Depreciation and amortization

3,483

Stock-based compensation

1,864

1,933

Amortization of premium (discount) on short-term investments

(3)

233

Interest added to the principal balance of the non-recourse term notes due 2029

683

6,427

Amortization of debt issuance costs

699

764

Realized gain on sale of marketable securities, net

(1,204)

Other non-cash items

(2)

Changes in operating assets and liabilities:

Receivables from collaborative arrangements

(1,311)

311

Prepaid expenses and other current assets

(161)

121

Accounts payable

(242)

1,025

Payable to Theravance Biopharma, Inc., net

(930)

Accrued personnel-related expenses and other accrued liabilities

(625)

(1,516)

Accrued interest payable

(1,349)

(1,356)

Other long-term liabilities

(2)

(16)

Deferred revenue

(221)

(222)

Net cash provided by (used in) operating activities

7,250

(1,616)

Cash flows from investing activities

Maturities of marketable securities

27,671

25,075

Purchases of marketable securities

(15,978)

(8,457)

Sales of marketable securities

57,098

Purchases of property and equipment

(6)

Net cash provided by investing activities

11,693

73,710

Cash flows from financing activities

Repurchase of common stock

(25,357)

Payments of cash dividends to stockholders

(719)

(28,794)

Repurchase of shares to satisfy tax withholding

(442)

(661)

Proceeds from issuances of common stock, net

173

1,747

Net cash used in financing activities

(26,345)

(27,708)

Net increase (decrease) in cash and cash equivalents

(7,402)

44,386

Cash and cash equivalents at beginning of period

159,180

^[1]

96,800

Cash and cash equivalents at end of period

151,778

141,186

Supplemental disclosure of cash flow information

Cash paid for interest

$ 13,124

$ 6,870

[1]	Condensed consolidated balance sheet as of December 31, 2015 has been derived from audited consolidated financial statements.

Description of Operations and Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2016
Description of Operations and Summary of Significant Accounting Policies
Description of Operations and Summary of Significant Accounting Policies	1. Description of Operations and Summary of Significant Accounting Policies Description of Operations Innoviva, Inc. (referred to as “Innoviva”, the “Company”, or “we” and other similar pronouns) is focused on bringing compelling new medicines to patients in areas of unmet need by leveraging its significant expertise in the development, commercialization and financial management of bio-pharmaceuticals. Innoviva’s portfolio is anchored by the respiratory assets partnered with Glaxo Group Limited (“GSK”), including RELVAR®/BREO® ELLIPTA® (fluticasone furoate/ vilanterol, “FF/VI”) and ANORO® ELLIPTA® (umeclidinium bromide/ vilanterol, “UMEC/VI”). Under the Long-Acting Beta2 Agonist (“LABA”) Collaboration Agreement and the Strategic Alliance Agreement with GSK (referred to herein as the “GSK Agreements”), Innoviva is eligible to receive the associated royalty revenues from RELVAR®/BREO® ELLIPTA® and ANORO® ELLIPTA®. Innoviva is also entitled to 15% of any future payments made by GSK under its agreements originally entered into with us, and since assigned to Theravance Respiratory Company, LLC (“TRC”), relating to the combination FF/UMEC/VI and the Bifunctional Muscarinic Antagonist- Beta2 Agonist (“MABA”) program, as monotherapy and in combination with other therapeutically active components, such as an inhaled corticosteroid, and any other product or combination of products that may be discovered and developed in the future under the LABA Collaboration Agreement (“LABA Collaboration”), which has been assigned to TRC other than RELVAR®/BREO®ELLIPTA® and ANORO® ELLIPTA®. Basis of Presentation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information. Accordingly, they do not include all of the information and notes required by GAAP for complete financial statements. In our opinion, the unaudited condensed consolidated financial statements have been prepared on the same basis as audited consolidated financial statements and include all adjustments, consisting of only normal recurring adjustments, necessary for the fair presentation of our financial position, results of operations, comprehensive income and cash flows. The interim results are not necessarily indicative of the results of operations to be expected for the year ending December 31, 2016 or any other period. The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2015 filed with the Securities and Exchange Commission (“SEC”) on February 24, 2016. Prior Period Reclassifications Certain reclassifications of prior period amounts have been made to conform to the current period presentation. Refer to section on “Recently Adopted Accounting Pronouncement” below. Variable Interest Entity We evaluate our ownership, contractual and other interest in entities to determine if they are variable interest entities (“VIE”), whether we have a variable interest in those entities and the nature and extent of those interests. Based on our evaluations, if we determine we are the primary beneficiary of such VIEs, we consolidate such entities into our financial statements. We consolidate the financial results of TRC, which we have determined to be a VIE, because we have the power to direct the economically significant activities of TRC and the obligation to absorb losses of, or the right to receive benefits from, TRC. The financial position and results of operations of TRC are not material for the periods presented. Recently Issued Accounting Pronouncements Not Yet Adopted In February 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2016-02, Leases, which supersedes the lease recognition requirements in ASC Topic 840, Leases. The standard requires an entity to recognize right-of-use assets and lease liabilities arising from a lease for both financing and operating leases in the consolidated balance sheets but recognize the impact on the consolidated statement of operations and cash flows in a similar manner under current GAAP. The standard also requires additional qualitative and quantitative disclosures. The standard is effective for us beginning January 1, 2019, although early adoption is permitted. We are currently evaluating adoption methods and whether this standard will have a material impact on our consolidated financial statements. In January 2016, the FASB issued ASU 2016-01, Recognition and Measurement of Financial Assets and Financial Liabilities, which provides guidance for the recognition, measurement, presentation, and disclosure of financial assets and liabilities. This standard is effective for us beginning January 1, 2018. We are evaluating the effects of the adoption of this ASU to our consolidated financial statements. In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers (“ASU 2014-09”), requiring an entity to recognize the amount of revenue to which it expects to be entitled to in exchange for the transfer of promised goods or services to customers. The standard will replace nearly all existing revenue recognition guidance under GAAP when it becomes effective. In July 2015, the FASB decided to defer the effective date by one year. Thus, the standard will be effective for us beginning January 1, 2018, at which time we may adopt the standard under either the full retrospective method or the modified retrospective method. Early adoption on or after January 1, 2017 would be permitted. We are currently evaluating the effect that the new standard will have on our consolidated financial statements and related disclosures. Recently Adopted Accounting Pronouncement In April 2015, the FASB issued ASU 2015-03, Interest — Imputation of Interest (“ASU 2015-03”), to simplify the presentation of debt issuance costs. This standard amended existing guidance to require the presentation of debt issuance costs associated with term loans in the balance sheet as a deduction from the carrying amount of the related debt liability instead of a deferred charge. We adopted ASU 2015-03 on January 1, 2016. Upon adoption of ASU 2015-03, we applied the guidance retrospectively to all periods presented and classified our debt issuance costs, which prior to adoption were included in other assets in the condensed consolidated financial statements, as a deduction to our respective long-term debts.

Net Income (Loss) per Share

3 Months Ended

Mar. 31, 2016

Net Income (Loss) per Share

Net Income (Loss) per Share

2. Net Income (Loss) per Share

Basic net income (loss) per share is computed by dividing net income (loss) by the weighted-average number of shares of common shares outstanding. Diluted net income (loss) per share is computed by dividing net income (loss) by the weighted-average number of shares of common shares and dilutive potential common share equivalents then outstanding. Dilutive potential common share equivalents include the assumed exercise, vesting and issuance of employee stock awards using the treasury stock method, as well as common shares issuable upon assumed conversion of our convertible debt using the if-converted method.

The following table shows the computation of basic and diluted net income per share for the three months ended March 31, 2016 and 2015:

	Three Months Ended March 31,
(In thousands except for per share amounts)	2016 (1)		2015
Numerator:
Net income (loss), basic and diluted	$	4,435	$	(10,667	)

Denominator:
Weighted-average shares used to compute basic net income (loss) per share	112,482		114,658
Dilutive effect of options and awards granted under equity incentive plan and employee stock purchase plan	196		—
Dilutive effect of unvested restricted stock awards (“RSAs”)	500		—

Weighted-average shares used to compute diluted net income (loss) per share	113,178		114,658


Net income (loss) per share
Basic	$	0.04	$	(0.09	)

Diluted	$	0.04	$	(0.09	)

Anti-Dilutive Securities

The following common share equivalents were not included in the computation of diluted net income (loss) per share because their effect was anti-dilutive:

	Three Months Ended March 31,
(In thousands)	2016 (1)	2015 (2)
Outstanding options and awards granted under equity incentive plan and employee stock purchase plan	3,917	5,866
Unvested RSAs	510	1,930
Shares issuable upon conversion of convertible subordinated notes	12,904	12,494

	17,331	20,290

(1)

Includes 3.3 million options, 0.1 million restricted stock units, and 0.4 million unvested RSAs retained by former employees who were transferred to Theravance Biopharma, Inc. (“Theravance Biopharma”) in connection with the Spin-Off of Theravance Biopharma in June 2014 (the “Spin-Off”). Subsequent to the Spin-Off, stock-based compensation expense associated with the awards held by Theravance Biopharma employees granted prior to the Spin-Off is recognized by Theravance Biopharma. Stock options of 3.3 million were excluded from the diluted net income per share calculation as their effect was anti-dilutive.

(2)

Includes 4.5 million options, 0.6 million restricted stock units, and 1.2 million unvested RSAs retained by former employees who were transferred to Theravance Biopharma in connection with the Spin-Off. All of these awards were excluded from the diluted net loss per share calculation as their effect was anti-dilutive.

Collaborative Arrangements

3 Months Ended

Mar. 31, 2016

Collaborative Arrangements

Collaborative Arrangements

3. Collaborative Arrangements

Net Revenue from Collaborative Arrangements

Net revenue recognized under our GSK Agreements was as follows:

	Three Months Ended March 31,
(In thousands)	2016			2015
Royalties from a related party	$	27,411		$	10,130
Less: amortization of capitalized fees paid to a related party	(3,456		)	(3,456		)

Royalty revenue	23,955			6,674
Strategic alliance - MABA program	221			222

Total net revenue from GSK	$	24,176		$	6,896

LABA Collaboration

As a result of the launch and approval of RELVAR®/BREO® ELLIPTA® and ANORO® ELLIPTA® in the U.S., Japan and Europe, we paid milestone fees to GSK totaling $220.0 million during the year ended December 31, 2014. Although we have no further milestone payment obligations to GSK pursuant to the LABA Collaboration Agreement, we continue to have ongoing development and commercialization activities under the GSK Agreements that are expected to continue over the life of the agreements. The milestone fees paid to GSK were recognized as capitalized fees paid to a related party, which are being amortized over their estimated useful lives commencing upon the commercial launch of the product. The amortization expense is recorded as a reduction to the royalties from GSK.

We are entitled to receive annual royalties from GSK on sales of RELVAR®/BREO® ELLIPTA® as follows: 15% on the first $3.0 billion of annual global net sales and 5% for all annual global net sales above $3.0 billion. Sales of single-agent LABA medicines and combination medicines would be combined for the purposes of this royalty calculation. For other products combined with a LABA from the LABA Collaboration, such as ANORO® ELLIPTA®, royalties are upward tiering and range from 6.5% to 10%.

Agreements Entered into with GSK in Connection with the Spin-Off

On March 3, 2014, in contemplation of the Spin-Off, we, Theravance Biopharma and GSK entered into a series of agreements, including amendments to the GSK Agreements, clarifying how the companies would implement the Spin-Off and operate following the Spin-Off. Pursuant to a three-way master agreement, by and among us, Theravance Biopharma and GSK, we agreed to sell a certain number of Theravance Biopharma shares withheld from a taxable dividend of Theravance Biopharma shares to GSK. After such Theravance Biopharma shares were sent to the transfer agent, we agreed to purchase the Theravance Biopharma shares from the transfer agent, rather than have them sold on the open market, in order to satisfy tax withholdings. GSK had a right to purchase these shares of Theravance Biopharma from us, but this right expired unexercised. During the three months ended March 31, 2015, we sold all 436,802 ordinary shares of Theravance Biopharma that we held as of December 31, 2014. Refer to Note 4 “Available-for-Sale Securities and Fair Value Measurements” for further information.

GSK Contingent Payments and Revenue

The potential future contingent payments receivable related to the MABA program of $363 million are not deemed substantive milestones due to the fact that the achievement of the event underlying the payment predominantly relates to GSK’s performance of future development, manufacturing and commercialization activities for product candidates after licensing the program. We are entitled to 15% of any milestone payments.

Available-for-Sale Securities and Fair Value Measurements

3 Months Ended

Mar. 31, 2016

Available-for-Sale Securities and Fair Value Measurements

Available-for-Sale Securities and Fair Value Measurements

4. Available-for-Sale Securities and Fair Value Measurements

Available-for-Sale Securities

The classification of available-for-sale securities in the condensed consolidated balance sheets is as follows:

(In thousands)	March 31, 2016		December 31, 2015
Cash and cash equivalents	$	148,316	$	148,673
Short-term marketable securities	16,414		28,103

Total	$	164,730	$	176,776

The estimated fair value of available-for-sale securities is based on quoted market prices for these or similar investments that were based on prices obtained from a commercial pricing service. Available-for-sale securities are summarized below:

	March 31, 2016
(In thousands)	Amortized Cost		Gross Unrealized Losses			Estimated Fair Value
U.S. government agencies	$	6,532	$	(1	)	$	6,531
U.S. corporate notes	1,632		—			1,632
U.S. commercial paper	69,557		—			69,557
Money market funds	87,010		—			87,010

Total	$	164,731	$	(1	)	$	164,730

	December 31, 2015
(In thousands)	Amortized Cost		Gross Unrealized Losses			Estimated Fair Value
U.S. government agencies	$	14,406	$	(1	)	$	14,405
U.S. corporate notes	2,702		(1		)	2,701
U.S. commercial paper	10,997		—			10,997
Money market funds	148,673		—			148,673

Total	$	176,778	$	(2	)	$	176,776

As of March 31, 2016, all of the available-for-sale securities had contractual maturities within one year and the weighted average maturity of marketable securities was approximately two months. We do not intend to sell the investments in debt that are in an unrealized loss position, and it is unlikely that we will be required to sell the investments before recovery of their amortized cost basis, which may be maturity. We have determined that the gross unrealized losses on our marketable securities as of March 31, 2016 were temporary in nature. As of March 31, 2016, all marketable securities with unrealized losses have been in a loss position for less than twelve months.

During the three months ended March 31, 2015, we sold all of the ordinary shares of Theravance Biopharma, which resulted in a gain on sale of $1.2 million, which is included in other income (expense), net in the condensed consolidated statement of operations.

Fair Value Measurements

Our available-for-sale securities are measured at fair value on a recurring basis and our debt is carried at the amortized cost basis. The estimated fair values were as follows:

	Estimated Fair Value Measurements as of March 31, 2016 Using:
Types of Instruments	Quoted Price in Active Markets for Identical Assets		Significant Other Observable Inputs		Significant Unobservable Inputs
(In thousands)	Level 1		Level 2		Level 3		Total
Assets
U.S. government agencies	$	—	$	6,531	$	—	$	6,531
U.S. corporate notes	—		1,632		—		1,632
U.S. commercial paper	—		69,557		—		69,557
Money market funds	87,010		—		—		87,010

Total assets measured at estimated fair value	$	87,010	$	77,720	$	—	$	164,730

Liabilities
Convertible subordinated notes due 2023	$	—	$	199,304	$	—	$	199,304
Non-recourse notes due 2029	—		471,622		—		471,622

Total fair value of liabilities	$	—	$	670,926	$	—	$	670,926

	Estimated Fair Value Measurements as of December 31, 2015 Using:
Types of Instruments	Quoted Price in Active Markets for Identical Assets		Significant Other Observable Inputs		Significant Unobservable Inputs
(In thousands)	Level 1		Level 2		Level 3		Total
Assets
U.S. government agencies	$	—	$	14,405	$	—	$	14,405
U.S. corporate notes	—		2,701		—		2,701
U.S. commercial paper	—		10,997		—		10,997
Money market funds	148,673		—		—		148,673

Total assets measured at estimated fair value	$	148,673	$	28,103	$	—	$	176,776

Liabilities
Convertible subordinated notes due 2023	$	—	$	189,100	$	—	$	189,100
Non-recourse notes due 2029	—		470,970		—		470,970

Total fair value of liabilities	$	—	$	660,070	$	—	$	660,070

The fair value of our marketable securities classified within Level 2 is based upon observable inputs that may include benchmark yields, reported trades, broker/dealer quotes, issuer spreads, two-sided markets, benchmark securities, bids, offers and reference data including market research publications.

The fair value of our convertible subordinated notes due 2023 and non-recourse notes due 2029 is based on recent trading prices of the instruments.

Capitalized Fees Paid to a Related Party

3 Months Ended

Mar. 31, 2016

Capitalized Fees Paid to a Related Party

Capitalized Fees Paid to a Related Party

5. Capitalized Fees Paid to a Related Party

Capitalized fees paid to a related party, which consist of registrational and launch-related milestone fees paid to GSK, were as follows:

March 31, 2016

December 31, 2015

Weighted

Average

Remaining

Amortization

Gross

Net

Gross

Net

Period

Carrying

Accumulated

Carrying

Accumulated

Carrying

(In thousands)

(Years)

Value

Amortization

Value

Amortization

Value

Approval and launch related milestone payments under the LABA Collaboration

13.9

220,000

(29,088

)

190,912

220,000

(25,632

)

194,368

These milestone fees are being amortized over their estimated useful lives commencing upon the commercial launch of the product in their respective regions with the amortization expense recorded as a reduction in revenue from collaborative arrangements. Additional information regarding these milestone fees is included in Note 3, “Collaborative Arrangements.” Amortization expense for the three months ended March 31, 2016 and 2015 was $3.5 million. As of March 31, 2016, the remaining estimated amortization expense is $10.4 million for 2016, $13.8 million for each of the years from 2017 to 2021, and $111.4 million thereafter.

Stock-Based Compensation

3 Months Ended

Mar. 31, 2016

Stock-Based Compensation

Stock-Based Compensation

6. Stock-Based Compensation

Performance-Contingent RSAs and RSUs

Since 2011, the Compensation Committee of our Board of Directors (the “Compensation Committee”) have approved grants of performance-contingent RSAs and RSUs to senior management and a non-executive officer. Generally, these awards have dual triggers of vesting based upon the achievement of certain performance goals by a pre-specified date, as well as a requirement for continued employment. Recognition of stock-based compensation expense begins when the performance goals are deemed probable of achievement.

Included in these performance-contingent RSAs is the grant of 1,290,000 special long-term retention and incentive performance-contingent RSAs to senior management in 2011. The awards have dual triggers of vesting based upon the achievement of certain performance conditions over a six-year timeframe from 2011 through December 31, 2016 and require continued employment. In connection with the Spin-Off, our Compensation Committee approved the modification of the remaining tranches related to these awards as the performance conditions associated with the remaining portions of these awards were unlikely to be consistent with the new strategies of each company following the Spin-Off. The remaining 63,000 RSAs for which service-based vesting was not triggered at the time of the Spin-Off remain subject to new performance conditions (as well as the original service conditions). In addition, the RSAs for which both the performance and service-based conditions were not achieved prior to the Spin-Off were entitled to the pro rata dividend distribution made by Innoviva on June 2, 2014 of one ordinary share of Theravance Biopharma for every 3.5 shares of Innoviva common stock subject to their awards, which will also be subject to the same new performance and service conditions as the original RSAs to which they relate. As of March 31, 2016, we determined that the achievement of the requisite performance conditions was not probable and, as a result, no compensation cost was recognized for the remaining equity awards.

On January 14, 2016, the Compensation Committee approved and granted 282,394 RSAs and 46,294 RSUs to senior management. These awards include a market condition based on Relative Total Shareholder Return (“TSR”) and a service condition that requires continued employment, collectively the “Performance Measures”. The vesting percentages of these awards are calculated based on the two-year TSR with a catch-up provision opportunity measured on January 13, 2019 for RSAs and on September 30, 2018 for RSUs. Two-thirds of amounts earned at the end of year two will vest and be distributed on February 20, 2018, while the final one-third earned after two years as well as the catch up amount earned will vest and be distributed on February 20, 2019 for RSAs and November 20, 2018 for RSUs. The actual payout of shares may range from a minimum of zero shares to a maximum of 328,688 shares granted upon the actual performance against the Performance Measures. The grant date fair value of these awards is determined using a Monte Carlo valuation model. The aggregate value of $2.0 million is recognized as compensation expense over the service period and is not reversed if the market condition is not met.

Stock-Based Compensation Expense

Stock-based compensation expense is included in the condensed consolidated statements of operations as follows:

	Three Months Ended March 31,
(In thousands)	2016		2015
Research and development	$	175	$	235
General and administrative	1,689		1,698

Total stock-based compensation expense	$	1,864	$	1,933

As of March 31, 2016, unrecognized compensation expense, net of expected forfeitures for awards expected to vest, including the market based awards was as follows: $1.4 million related to unvested stock options; $1.5 million related to unvested RSUs; and $12.0 million related to unvested RSAs.

At the time of the Spin-Off, all outstanding stock options, RSUs and RSAs held by former employees and directors, who transferred to Theravance Biopharma, were retained by them. As the vesting of these options and awards is based on continuing employment or service with Theravance Biopharma, all stock-based compensation expense associated with these options and awards is recognized by Theravance Biopharma.

Valuation Assumptions

No options were granted for the three months ended March 31, 2016 and 2015.

Long-Term Debt

3 Months Ended

Mar. 31, 2016

Long-Term Debt.

Long-Term Debt

7. Long-Term Debt

Our long-term debt consists of:

(In thousands)	March 31, 2016		December 31, 2015
Convertible Subordinated Notes due 2023	$	255,109	$	255,109
Non-Recourse Notes Payable due 2029	493,845		493,162

Total long-term debt	748,954		748,271
Less: unamortized debt issuance costs	14,441		15,140

Net long-term debt	$	734,513	$	733,131

Convertible Subordinated Notes Due 2023

In January 2013, we completed an underwritten public offering of $287.5 million aggregate principal amount of unsecured convertible subordinated notes, which will mature on January 15, 2023 (the “2023 Notes”). The financing raised proceeds, net of issuance costs, of approximately $281.2 million, less $36.8 million to purchase two privately-negotiated capped call option transactions in connection with the issuance of the notes. The 2023 Notes bear interest at the rate of 2.125% per year that is payable semi-annually in arrears in cash on January 15 and July 15 of each year, beginning on July 15, 2013.

The 2023 Notes were convertible, at the option of the holder, into shares of our common stock at an initial conversion rate of 35.9903 shares per $1,000 principal amount of the 2023 Notes, subject to adjustment in certain circumstances, which represents an initial conversion price of approximately $27.79 per share. Following the Spin-Off of Theravance Biopharma, a number of adjustments to the initial conversion rate have been made as described below. Holders of the 2023 Notes will be able to require us to repurchase some or all of their notes upon the occurrence of a fundamental change, as defined in the 2013 Notes, at 100% of the principal amount of the notes being repurchased plus accrued and unpaid interest. We may not redeem the notes prior to their stated maturity date.

In connection with the offering of the 2023 Notes, we entered into two privately-negotiated capped call option transactions with a single counterparty. The capped call option transaction is an integrated instrument consisting of a call option on our common stock purchased by us with a strike price equal to the initial conversion price of $27.79 per share for the underlying number of shares and a cap price of $38.00 per share, both of which are subject to adjustments consistent with the 2023 Notes. The cap component is economically equivalent to a call option sold by us for the underlying number of shares with an initial strike price of $38.00 per share. As an integrated instrument, the settlement of the capped call coincides with the due date of the convertible debt. Upon settlement, we would receive from our hedge counterparty a number of shares of our common shares that would range from zero, if the stock price was below $27.79 per share, to a maximum of 2,779,659 shares, if the stock price is above $38.00 per share. However, if the market price of our common stock, as measured under the terms of the capped call transactions, exceeds $38.00 per share, there is no incremental anti-dilutive benefit from the capped call.

In accordance with the agreement for the 2023 Notes, the conversion rate was adjusted as a result of the completion of the Spin-Off of Theravance Biopharma. The conversion rate was adjusted based on the conversion rate immediately prior to the record date for the Spin-Off and the average of the stock dividend distributed to our common stockholders and our stock prices. This resulted in an adjusted conversion rate of 46.9087 shares per $1,000 principal amount of the 2023 Notes, which represents an adjusted conversion price of approximately $21.32 per share. As a result of the conversion rate adjustment, the capped call strike price and cap price were also adjusted accordingly to $21.32 and $29.16, respectively. On July 15, 2014, certain holders of the 2023 Notes converted their notes into 1,519,402 shares of our common stock at the adjusted conversion price of $21.32 per share. In connection with the partial conversion of the 2023 Notes, we received 149,645 shares of our common stock from our capped call option counterparty and the shares of common stock received were recorded as treasury stock.

In connection with the payments of the cash dividends during the year ended December 31, 2015 and 2014, the adjusted conversion rate with respect to our 2023 Notes was further adjusted in total from 46.9087 shares of our common stock per $1,000 principal amount of the 2023 Notes to 50.5818 shares of our common stock per $1,000 principal amount of the 2023 Notes, which represents an adjusted conversion price of approximately $19.77 per share. As a result of the conversion rate adjustment, the capped call strike price and cap price were also adjusted accordingly to $19.77 and $27.04.

Non-Recourse Notes Due 2029

In April 2014, we entered into certain note purchase agreements relating to the private placement of $450.0 million aggregate principal amount of non-recourse fixed rate term notes due 2029 (the “2029 Notes”) issued by our wholly-owned subsidiary.

The 2029 Notes bear an annual interest rate of 9%, with interest and principal paid quarterly beginning November 15, 2014. The 2029 Notes may be redeemed at any time prior to maturity, in whole or in part, at specified redemption premiums. Prior to and including May 15, 2016, in the event that the specified portion of royalties received in a quarter is less than the interest accrued for the quarter, the principal amount of the 2029 Notes will increase by the interest shortfall amount for that period, and considered as payment in kind (“PIK”). Since issuance, $43.8 million of interest expense has been added to the principal balance of the 2029 Note, of which $0.7 million and $6.4 million was added during the three months ended March 31, 2016 and 2015, respectively. Since the principal and interest payments on the 2029 Notes are based on royalties from product sales recorded by GSK, which will vary from quarter to quarter and are unknown to us, the 2029 Notes may be repaid prior to the final maturity date in 2029. The 2029 Notes can be prepaid subject to a prepayment premium of 2.5% until April 17, 2017, and without premium afterwards.

Shareholders' Deficit	3 Months Ended
Shareholders' Deficit	Mar. 31, 2016
Shareholders' Deficit
Shareholders' Deficit	8. Shareholders’ Deficit For the three months ended March 31, 2016, we repurchased 2,449,632 shares of our common stock in the open market at an average price of $10.35 per share for a total purchase price of $25.4 million, which were retired upon repurchase.

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(d),(e))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB TOPIC 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29-31)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB TOPIC 4.C)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Preferred Stock
-URI http://asc.fasb.org/extlink&oid=6521494

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section E

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section C

+ Details

Commitments and Contingencies	3 Months Ended
Commitments and Contingencies	Mar. 31, 2016
Commitments and Contingencies
Commitments and Contingencies	9. Commitments and Contingencies Operating Lease and Lease Guarantee Upon the Spin-Off, our facility leases in South San Francisco, California were assigned to Theravance Biopharma. However, if Theravance Biopharma were to default on its lease obligations, we would be held liable by the landlord and thus, we have in substance guaranteed the lease payments for these facilities. We would also be responsible for lease-related payments including utilities, property taxes, and common area maintenance, which may be as much as the actual lease payments. As of March 31, 2016, the total remaining lease payments, which run through May 2020, were $26.2 million. The carrying value of this lease guarantee was $1.3 million as of March 31, 2016 and is reflected in other long-term liabilities in our consolidated balance sheet.

Income Taxes	3 Months Ended
Income Taxes	Mar. 31, 2016
Income Taxes
Income Taxes	10. Income Taxes The effective tax rate for the three months ended March 31, 2016 was 0.15%, compared to 0.00% for the same period in 2015. Should we generate taxable income in 2016, we expect that the taxable income will be substantially offset by the utilization of net operating losses or other deferred tax assets. The difference between the consolidated effective income tax rate and the U.S. federal statutory rate is primarily attributable to a change in valuation allowance against net deferred tax assets.

Description of Operations and Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2016
Description of Operations and Summary of Significant Accounting Policies
Basis of Presentation	Basis of Presentation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information. Accordingly, they do not include all of the information and notes required by GAAP for complete financial statements. In our opinion, the unaudited condensed consolidated financial statements have been prepared on the same basis as audited consolidated financial statements and include all adjustments, consisting of only normal recurring adjustments, necessary for the fair presentation of our financial position, results of operations, comprehensive income and cash flows. The interim results are not necessarily indicative of the results of operations to be expected for the year ending December 31, 2016 or any other period. The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2015 filed with the Securities and Exchange Commission (“SEC”) on February 24, 2016.
Prior Period Reclassifications	Prior Period Reclassifications Certain reclassifications of prior period amounts have been made to conform to the current period presentation. Refer to section on “Recently Adopted Accounting Pronouncement” below.
Variable Interest Entity	Variable Interest Entity We evaluate our ownership, contractual and other interest in entities to determine if they are variable interest entities (“VIE”), whether we have a variable interest in those entities and the nature and extent of those interests. Based on our evaluations, if we determine we are the primary beneficiary of such VIEs, we consolidate such entities into our financial statements. We consolidate the financial results of TRC, which we have determined to be a VIE, because we have the power to direct the economically significant activities of TRC and the obligation to absorb losses of, or the right to receive benefits from, TRC. The financial position and results of operations of TRC are not material for the periods presented.
Recently Issued Accounting Pronouncements Not Yet Adopted	Recently Issued Accounting Pronouncements Not Yet Adopted In February 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2016-02, Leases, which supersedes the lease recognition requirements in ASC Topic 840, Leases. The standard requires an entity to recognize right-of-use assets and lease liabilities arising from a lease for both financing and operating leases in the consolidated balance sheets but recognize the impact on the consolidated statement of operations and cash flows in a similar manner under current GAAP. The standard also requires additional qualitative and quantitative disclosures. The standard is effective for us beginning January 1, 2019, although early adoption is permitted. We are currently evaluating adoption methods and whether this standard will have a material impact on our consolidated financial statements. In January 2016, the FASB issued ASU 2016-01, Recognition and Measurement of Financial Assets and Financial Liabilities, which provides guidance for the recognition, measurement, presentation, and disclosure of financial assets and liabilities. This standard is effective for us beginning January 1, 2018. We are evaluating the effects of the adoption of this ASU to our consolidated financial statements. In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers (“ASU 2014-09”), requiring an entity to recognize the amount of revenue to which it expects to be entitled to in exchange for the transfer of promised goods or services to customers. The standard will replace nearly all existing revenue recognition guidance under GAAP when it becomes effective. In July 2015, the FASB decided to defer the effective date by one year. Thus, the standard will be effective for us beginning January 1, 2018, at which time we may adopt the standard under either the full retrospective method or the modified retrospective method. Early adoption on or after January 1, 2017 would be permitted. We are currently evaluating the effect that the new standard will have on our consolidated financial statements and related disclosures.
Recently Adopted Accounting Pronouncement	Recently Adopted Accounting Pronouncement In April 2015, the FASB issued ASU 2015-03, Interest — Imputation of Interest (“ASU 2015-03”), to simplify the presentation of debt issuance costs. This standard amended existing guidance to require the presentation of debt issuance costs associated with term loans in the balance sheet as a deduction from the carrying amount of the related debt liability instead of a deferred charge. We adopted ASU 2015-03 on January 1, 2016. Upon adoption of ASU 2015-03, we applied the guidance retrospectively to all periods presented and classified our debt issuance costs, which prior to adoption were included in other assets in the condensed consolidated financial statements, as a deduction to our respective long-term debts.

- Definition

Disclosure of accounting policy for consolidation to describe the significant judgments and assumptions made in determining whether a variable interest held by the entity requires the variable interest entity to be consolidated and (or) disclose information about its involvement with the variable interest entity; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; and the significant factors considered and judgments made in determining that the power to direct the activities that significantly impact the economic performance of the variable interest entity are shared (as defined).

+ References + Details

Net Income (Loss) per Share (Tables)

3 Months Ended

Mar. 31, 2016

Net Income (Loss) per Share

Schedule of computation of basic and diluted net income per share

	Three Months Ended March 31,
(In thousands except for per share amounts)	2016 (1)		2015
Numerator:
Net income (loss), basic and diluted	$	4,435	$	(10,667	)

Denominator:
Weighted-average shares used to compute basic net income (loss) per share	112,482		114,658
Dilutive effect of options and awards granted under equity incentive plan and employee stock purchase plan	196		—
Dilutive effect of unvested restricted stock awards (“RSAs”)	500		—

Weighted-average shares used to compute diluted net income (loss) per share	113,178		114,658


Net income (loss) per share
Basic	$	0.04	$	(0.09	)

Diluted	$	0.04	$	(0.09	)

(1)

Schedule of anti-dilutive securities

	Three Months Ended March 31,
(In thousands)	2016 (1)	2015 (2)
Outstanding options and awards granted under equity incentive plan and employee stock purchase plan	3,917	5,866
Unvested RSAs	510	1,930
Shares issuable upon conversion of convertible subordinated notes	12,904	12,494

	17,331	20,290

(1)

(2)

Collaborative Arrangements (Tables)

3 Months Ended

Mar. 31, 2016

Collaborative Arrangements

Schedule of net revenue recognized under GSK Agreements

	Three Months Ended March 31,
(In thousands)	2016			2015
Royalties from a related party	$	27,411		$	10,130
Less: amortization of capitalized fees paid to a related party	(3,456		)	(3,456		)

Royalty revenue	23,955			6,674
Strategic alliance - MABA program	221			222

Total net revenue from GSK	$	24,176		$	6,896

Available-for-Sale Securities and Fair Value Measurements (Tables)

3 Months Ended

Mar. 31, 2016

Available-for-Sale Securities and Fair Value Measurements

Schedule of available-for-sale securities

(In thousands)	March 31, 2016		December 31, 2015
Cash and cash equivalents	$	148,316	$	148,673
Short-term marketable securities	16,414		28,103

Total	$	164,730	$	176,776

Schedule of amortized cost and estimated fair values for available-for-sale securities

	March 31, 2016
(In thousands)	Amortized Cost		Gross Unrealized Losses			Estimated Fair Value
U.S. government agencies	$	6,532	$	(1	)	$	6,531
U.S. corporate notes	1,632		—			1,632
U.S. commercial paper	69,557		—			69,557
Money market funds	87,010		—			87,010

Total	$	164,731	$	(1	)	$	164,730

	December 31, 2015
(In thousands)	Amortized Cost		Gross Unrealized Losses			Estimated Fair Value
U.S. government agencies	$	14,406	$	(1	)	$	14,405
U.S. corporate notes	2,702		(1		)	2,701
U.S. commercial paper	10,997		—			10,997
Money market funds	148,673		—			148,673

Total	$	176,778	$	(2	)	$	176,776

Schedule of estimated fair values

	Estimated Fair Value Measurements as of March 31, 2016 Using:
Types of Instruments	Quoted Price in Active Markets for Identical Assets		Significant Other Observable Inputs		Significant Unobservable Inputs
(In thousands)	Level 1		Level 2		Level 3		Total
Assets
U.S. government agencies	$	—	$	6,531	$	—	$	6,531
U.S. corporate notes	—		1,632		—		1,632
U.S. commercial paper	—		69,557		—		69,557
Money market funds	87,010		—		—		87,010

Total assets measured at estimated fair value	$	87,010	$	77,720	$	—	$	164,730

Liabilities
Convertible subordinated notes due 2023	$	—	$	199,304	$	—	$	199,304
Non-recourse notes due 2029	—		471,622		—		471,622

Total fair value of liabilities	$	—	$	670,926	$	—	$	670,926

	Estimated Fair Value Measurements as of December 31, 2015 Using:
Types of Instruments	Quoted Price in Active Markets for Identical Assets		Significant Other Observable Inputs		Significant Unobservable Inputs
(In thousands)	Level 1		Level 2		Level 3		Total
Assets
U.S. government agencies	$	—	$	14,405	$	—	$	14,405
U.S. corporate notes	—		2,701		—		2,701
U.S. commercial paper	—		10,997		—		10,997
Money market funds	148,673		—		—		148,673

Total assets measured at estimated fair value	$	148,673	$	28,103	$	—	$	176,776

Liabilities
Convertible subordinated notes due 2023	$	—	$	189,100	$	—	$	189,100
Non-recourse notes due 2029	—		470,970		—		470,970

Total fair value of liabilities	$	—	$	660,070	$	—	$	660,070

- Definition

Tabular disclosure of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.

+ References + Details

Capitalized Fees Paid to a Related Party (Tables)

3 Months Ended

Mar. 31, 2016

Capitalized Fees Paid to a Related Party

Schedule of capitalized fees paid to a related party

March 31, 2016

December 31, 2015

Weighted

Average

Remaining

Amortization

Gross

Net

Gross

Net

Period

Carrying

Accumulated

Carrying

Accumulated

Carrying

(In thousands)

(Years)

Value

Amortization

Value

Amortization

Value

Approval and launch related milestone payments under the LABA Collaboration

13.9

220,000

(29,088

)

190,912

220,000

(25,632

)

194,368

Stock-Based Compensation (Tables)

3 Months Ended

Mar. 31, 2016

Stock-Based Compensation

Schedule of allocation of stock-based compensation expense included in the condensed consolidated statements of operations

	Three Months Ended March 31,
(In thousands)	2016		2015
Research and development	$	175	$	235
General and administrative	1,689		1,698

Total stock-based compensation expense	$	1,864	$	1,933

Long-Term Debt (Tables)

3 Months Ended

Mar. 31, 2016

Long-Term Debt.

Schedule of long-term debt

(In thousands)	March 31, 2016		December 31, 2015
Convertible Subordinated Notes due 2023	$	255,109	$	255,109
Non-Recourse Notes Payable due 2029	493,845		493,162

Total long-term debt	748,954		748,271
Less: unamortized debt issuance costs	14,441		15,140

Net long-term debt	$	734,513	$	733,131

- Definition

Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 470
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6479336&loc=d3e64711-112823

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(e),(f))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 55
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=34725769&loc=d3e28878-108400

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21538-112644

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 1A
-URI http://asc.fasb.org/extlink&oid=6451184&loc=d3e28541-108399

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6451184&loc=d3e28551-108399

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21521-112644

+ Details

Description of Operations and Summary of Significant Accounting Policies (Details)	3 Months Ended
	Mar. 31, 2016
GSK \| LABA collaboration and Strategic Alliance agreements
Description of Operations and Summary of Significant Accounting Policies
Percentage of economic interest in any future payments made under the agreements	15.00%

Net Income (Loss) per Share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Numerator:
Net income (loss), basic and diluted	$ 4,435	$ (10,667)
Denominator:
Weighted-average shares used to compute basic net income (loss) per share	112,482	114,658
Weighted-average shares used to compute diluted net income (loss) per share	113,178	114,658
Net income (loss) per share
Basic (in dollars per share)	$ 0.04	$ (0.09)
Diluted (in dollars per share)	$ 0.04	$ (0.09)
Anti-dilutive securities (in shares)	17,331	20,290
Stock options
Net income (loss) per share
Anti-dilutive securities (in shares)	3,300	4,500
RSUs
Net income (loss) per share
Anti-dilutive securities (in shares)	100	600
Unvested RSAs
Net income (loss) per share
Anti-dilutive securities (in shares)	400	1,200
Equity incentive plans and ESPP
Denominator:
Dilutive effect of options and awards	196
Net income (loss) per share
Anti-dilutive securities (in shares)	3,917	5,866
Unvested RSAs
Denominator:
Dilutive effect of options and awards	500
Net income (loss) per share
Anti-dilutive securities (in shares)	510	1,930
Convertible subordinated notes
Net income (loss) per share
Anti-dilutive securities (in shares)	12,904	12,494

Collaborative Arrangements (Details) - USD ($) $ in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2016	Mar. 31, 2015	Dec. 31, 2014
Information related to collaborative arrangements
Less: amortization of capitalized fees paid to a related party	$ (3,456)	$ (3,456)
Royalty revenue	23,955	6,674
Revenue from collaborative arrangements	221	222
Total net revenue	24,176	$ 6,896
Theravance Biopharma \| Common Stock
Information related to collaborative arrangements
Number of ordinary shares sold		436,802
GSK
Information related to collaborative arrangements
Royalties from a related party	27,411	$ 10,130
Less: amortization of capitalized fees paid to a related party	(3,456)	(3,456)
Royalty revenue	23,955	6,674
Total net revenue	24,176	6,896
GSK \| MABA
Information related to collaborative arrangements
Potential future contingent payments receivable	$ 363,000
Percentage of milestone payment	15.00%
Long-acting beta agonist (LABA) collaboration \| GSK
Information related to collaborative arrangements
Less: amortization of capitalized fees paid to a related party	$ (3,500)	(3,500)
Milestone fees paid			$ 220,000
Obligation for milestone payments	$ 0
Royalty rate for first level of annual global net sales (as a percent)	15.00%
Annual global sales level used to determine royalty rate	$ 3,000,000
Royalty rate for sales above first level of annual global net sales (as a percent)	5.00%
Long-acting beta agonist (LABA) collaboration \| GSK \| Minimum
Information related to collaborative arrangements
Royalty rate for combination products (as a percent)	6.50%
Long-acting beta agonist (LABA) collaboration \| GSK \| Maximum
Information related to collaborative arrangements
Royalty rate for combination products (as a percent)	10.00%
2004 Strategic alliance \| GSK \| MABA
Information related to collaborative arrangements
Revenue from collaborative arrangements	$ 221	$ 222

Available-for-Sale Securities and Fair Value Measurements (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015	Dec. 31, 2015
Available-for-sale securities
Amortized Cost	$ 164,731		$ 176,778
Gross Unrealized Losses	(1)		(2)
Estimated Fair Value	$ 164,730		176,776
Maturity period for marketable securities
Maximum contractual maturity period	1 year
Average duration	2 months
Theravance Biopharma
Maturity period for marketable securities
Gain on sale		$ 1,200
Cash and cash equivalents
Available-for-sale securities
Estimated Fair Value	$ 148,316		148,673
Short-term marketable securities
Available-for-sale securities
Estimated Fair Value	16,414		28,103
U.S. government agencies
Available-for-sale securities
Amortized Cost	6,532		14,406
Gross Unrealized Losses	(1)		(1)
Estimated Fair Value	6,531		14,405
U.S. corporate notes
Available-for-sale securities
Amortized Cost	1,632		2,702
Gross Unrealized Losses	0		(1)
Estimated Fair Value	1,632		2,701
U.S. commercial paper
Available-for-sale securities
Amortized Cost	69,557		10,997
Gross Unrealized Losses	0		0
Estimated Fair Value	69,557		10,997
Money market funds
Available-for-sale securities
Amortized Cost	87,010		148,673
Gross Unrealized Losses	0		0
Estimated Fair Value	$ 87,010		$ 148,673

Available-for-Sale Securities and Fair Value Measurements (Details 2) - USD ($) $ in Thousands	Mar. 31, 2016	Dec. 31, 2015
Estimated fair values of entity's financial assets and liabilities
Total assets measured at fair value	$ 164,730	$ 176,776
U.S. government agencies
Estimated fair values of entity's financial assets and liabilities
Total assets measured at fair value	6,531	14,405
U.S. corporate notes
Estimated fair values of entity's financial assets and liabilities
Total assets measured at fair value	1,632	2,701
U.S. commercial paper
Estimated fair values of entity's financial assets and liabilities
Total assets measured at fair value	69,557	10,997
Money market funds
Estimated fair values of entity's financial assets and liabilities
Total assets measured at fair value	87,010	148,673
Recurring basis
Estimated fair values of entity's financial assets and liabilities
Total assets measured at fair value	164,730	176,776
Recurring basis \| U.S. government agencies
Estimated fair values of entity's financial assets and liabilities
Total assets measured at fair value	6,531	14,405
Recurring basis \| U.S. corporate notes
Estimated fair values of entity's financial assets and liabilities
Total assets measured at fair value	1,632	2,701
Recurring basis \| U.S. commercial paper
Estimated fair values of entity's financial assets and liabilities
Total assets measured at fair value	69,557	10,997
Recurring basis \| Money market funds
Estimated fair values of entity's financial assets and liabilities
Total assets measured at fair value	87,010	148,673
Recurring basis \| Quoted Prices in Active Markets for Identical Assets, Level 1
Estimated fair values of entity's financial assets and liabilities
Total assets measured at fair value	87,010	148,673
Recurring basis \| Quoted Prices in Active Markets for Identical Assets, Level 1 \| U.S. government agencies
Estimated fair values of entity's financial assets and liabilities
Total assets measured at fair value	0	0
Recurring basis \| Quoted Prices in Active Markets for Identical Assets, Level 1 \| U.S. corporate notes
Estimated fair values of entity's financial assets and liabilities
Total assets measured at fair value	0	0
Recurring basis \| Quoted Prices in Active Markets for Identical Assets, Level 1 \| U.S. commercial paper
Estimated fair values of entity's financial assets and liabilities
Total assets measured at fair value	0	0
Recurring basis \| Quoted Prices in Active Markets for Identical Assets, Level 1 \| Money market funds
Estimated fair values of entity's financial assets and liabilities
Total assets measured at fair value	87,010	148,673
Recurring basis \| Significant Other Observable Inputs, Level 2
Estimated fair values of entity's financial assets and liabilities
Total assets measured at fair value	77,720	28,103
Recurring basis \| Significant Other Observable Inputs, Level 2 \| U.S. government agencies
Estimated fair values of entity's financial assets and liabilities
Total assets measured at fair value	6,531	14,405
Recurring basis \| Significant Other Observable Inputs, Level 2 \| U.S. corporate notes
Estimated fair values of entity's financial assets and liabilities
Total assets measured at fair value	1,632	2,701
Recurring basis \| Significant Other Observable Inputs, Level 2 \| U.S. commercial paper
Estimated fair values of entity's financial assets and liabilities
Total assets measured at fair value	69,557	10,997
Recurring basis \| Significant Other Observable Inputs, Level 2 \| Money market funds
Estimated fair values of entity's financial assets and liabilities
Total assets measured at fair value	0	0
Recurring basis \| Significant Unobservable Inputs, Level 3
Estimated fair values of entity's financial assets and liabilities
Total assets measured at fair value	0	0
Recurring basis \| Significant Unobservable Inputs, Level 3 \| U.S. government agencies
Estimated fair values of entity's financial assets and liabilities
Total assets measured at fair value	0	0
Recurring basis \| Significant Unobservable Inputs, Level 3 \| U.S. corporate notes
Estimated fair values of entity's financial assets and liabilities
Total assets measured at fair value	0	0
Recurring basis \| Significant Unobservable Inputs, Level 3 \| U.S. commercial paper
Estimated fair values of entity's financial assets and liabilities
Total assets measured at fair value	0	0
Recurring basis \| Significant Unobservable Inputs, Level 3 \| Money market funds
Estimated fair values of entity's financial assets and liabilities
Total assets measured at fair value	0	0
Nonrecurring basis
Estimated fair values of entity's financial assets and liabilities
Total fair value of liabilities	670,926	660,070
Nonrecurring basis \| Convertible Subordinated Notes Due 2023
Estimated fair values of entity's financial assets and liabilities
Convertible subordinated notes due 2023	199,304	189,100
Nonrecurring basis \| 9% fixed rate term notes due 2029
Estimated fair values of entity's financial assets and liabilities
Non-recourse notes due 2029	471,622	470,970
Nonrecurring basis \| Quoted Prices in Active Markets for Identical Assets, Level 1
Estimated fair values of entity's financial assets and liabilities
Total fair value of liabilities	0	0
Nonrecurring basis \| Quoted Prices in Active Markets for Identical Assets, Level 1 \| Convertible Subordinated Notes Due 2023
Estimated fair values of entity's financial assets and liabilities
Convertible subordinated notes due 2023	0	0
Nonrecurring basis \| Quoted Prices in Active Markets for Identical Assets, Level 1 \| 9% fixed rate term notes due 2029
Estimated fair values of entity's financial assets and liabilities
Non-recourse notes due 2029	0	0
Nonrecurring basis \| Significant Other Observable Inputs, Level 2
Estimated fair values of entity's financial assets and liabilities
Total fair value of liabilities	670,926	660,070
Nonrecurring basis \| Significant Other Observable Inputs, Level 2 \| Convertible Subordinated Notes Due 2023
Estimated fair values of entity's financial assets and liabilities
Convertible subordinated notes due 2023	199,304	189,100
Nonrecurring basis \| Significant Other Observable Inputs, Level 2 \| 9% fixed rate term notes due 2029
Estimated fair values of entity's financial assets and liabilities
Non-recourse notes due 2029	471,622	470,970
Nonrecurring basis \| Significant Unobservable Inputs, Level 3
Estimated fair values of entity's financial assets and liabilities
Total fair value of liabilities	0	0
Nonrecurring basis \| Significant Unobservable Inputs, Level 3 \| Convertible Subordinated Notes Due 2023
Estimated fair values of entity's financial assets and liabilities
Convertible subordinated notes due 2023	0	0
Nonrecurring basis \| Significant Unobservable Inputs, Level 3 \| 9% fixed rate term notes due 2029
Estimated fair values of entity's financial assets and liabilities
Non-recourse notes due 2029	$ 0	$ 0

Capitalized Fees Paid to a Related Party (Details) - USD ($)
$ in Thousands

3 Months Ended

Mar. 31, 2016

Mar. 31, 2015

Dec. 31, 2015

Capitalized Fees paid to a Related Party

Net Carrying Value

$ 190,912

$ 194,368

^[1]

Amortization of capitalized fees paid to a related party

3,456

$ 3,456

Estimated amortization expense for the remainder of 2016

10,400

Estimated amortization expense for the year 2017

13,800

Estimated amortization expense for the year 2018

13,800

Estimated amortization expense for the year 2019

13,800

Estimated amortization expense for the year 2020

13,800

Estimated amortization expense for the year 2021

13,800

Estimated amortization expense thereafter

111,400

GSK

Capitalized Fees paid to a Related Party

Amortization of capitalized fees paid to a related party

$ 3,456

3,456

GSK | Long-acting beta agonist (LABA) collaboration

Capitalized Fees paid to a Related Party

Weighted Average Remaining Amortization Period

13 years 10 months 24 days

Gross Carrying Value

$ 220,000

220,000

Accumulated Amortization

(29,088)

(25,632)

Net Carrying Value

190,912

$ 194,368

Amortization of capitalized fees paid to a related party

$ 3,500

[1]	Condensed consolidated balance sheet as of December 31, 2015 has been derived from audited consolidated financial statements.

Stock-Based Compensation (Details) $ in Thousands			3 Months Ended		12 Months Ended
Stock-Based Compensation (Details) $ in Thousands	Jan. 14, 2016 shares	Jun. 02, 2014	Mar. 31, 2016 USD ($) shares	Mar. 31, 2015 USD ($)	Dec. 31, 2011 shares
Stock-based compensation
Number of shares of Theravance Biopharma issued for every share of Theravance		0.286
Stock-based compensation expense \| $			$ 1,864	$ 1,933
Minimum payout of shares (in shares)			0
Maximum payout of shares (in shares)			328,688
Market condition based on relative total shareholder return (TSR) And Service condition based on Performance Measures
Stock-based compensation
Timeframe for calculation of TSR			2 years
RSAs \| Vesting on February 20, 2018
Stock-based compensation
Portion of options vesting (as a percent)			66.70%
RSAs \| Vesting on February 20, 2019
Stock-based compensation
Portion of options vesting (as a percent)			33.30%
RSAs \| Market condition based on relative total shareholder return (TSR) And Service condition based on Performance Measures
Stock-based compensation
Granted (in shares)	282,394
RSUs \| Vesting on February 20, 2018
Stock-based compensation
Portion of options vesting (as a percent)			66.70%
RSUs \| Vesting on November 20, 2018
Stock-based compensation
Portion of options vesting (as a percent)			33.30%
RSUs \| Market condition based on relative total shareholder return (TSR) And Service condition based on Performance Measures
Stock-based compensation
Granted (in shares)	46,294
Special Long-Term Retention and Incentive Cash Awards Program \| RSAs \| Performance-contingent
Stock-based compensation
Shares of common stock approved and authorized for issuance					1,290,000
Timeframe for achievement of performance conditions					6 years
Outstanding (in shares)			63,000
Stock-based compensation expense \| $			$ 0

Stock-Based Compensation (Details 2) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Stock-based compensation
Stock-based compensation expense	$ 1,864	$ 1,933
Stock options
Stock-based compensation
Total unrecognized compensation cost related to unvested stock-based compensation	1,400
RSUs
Stock-based compensation
Total unrecognized compensation cost related to unvested stock-based compensation	1,500
Unvested RSAs
Stock-based compensation
Total unrecognized compensation cost related to unvested stock-based compensation	12,000
Research and development \| Continuing operations
Stock-based compensation
Stock-based compensation expense	175	235
General and administrative \| Continuing operations
Stock-based compensation
Stock-based compensation expense	$ 1,689	$ 1,698

Stock-Based Compensation (Details 3) - shares	3 Months Ended
Stock-Based Compensation (Details 3) - shares	Mar. 31, 2016	Mar. 31, 2015
Stock options
Compensation Awards
Options granted (in shares)	0	0

Long-Term Debt (Details) $ / shares in Units, $ in Thousands				1 Months Ended	3 Months Ended		18 Months Ended	37 Months Ended
	Jul. 15, 2014 $ / shares shares	Jun. 30, 2014 $ / shares $ / item	Jan. 31, 2013 USD ($) item $ / shares $ / item shares	Jan. 31, 2013 USD ($) item $ / shares $ / item	Mar. 31, 2016 USD ($) $ / shares $ / item	Mar. 31, 2015 USD ($)	Sep. 30, 2015 USD ($)	Apr. 17, 2017	Dec. 31, 2015 USD ($)	Apr. 30, 2014 USD ($)
Debt disclosures
Total long-term debt					$ 748,954				$ 748,271
Less: unamortized debt issuance costs					14,441				15,140
Net long-term debt					734,513				733,131
Interest amount added to principal balance					683	$ 6,427
Convertible Subordinated Notes Due 2023
Debt disclosures
Convertible Subordinated Notes due 2023					$ 255,109				255,109
Loan amount			$ 287,500	$ 287,500
Proceeds from issuances of note payable, net of debt issuance costs			$ 281,200
Interest rate (as a percent)			2.125%	2.125%
Conversion rate of shares		46.9087		35.9903	50.5818
Conversion price of convertible notes into common stock (in dollars per share) \| $ / shares		$ 21.32	$ 27.79	$ 27.79	$ 19.77
Percentage of principal amount at which the entity may be forced to redeem some or all notes as a result of a fundamental change (as defined)			100.00%
Convertible Subordinated Notes Due 2023 \| Common Stock
Debt disclosures
Conversion price of convertible notes into common stock (in dollars per share) \| $ / shares	$ 21.32
Debt Conversion, Converted Instrument, Shares Issued \| shares	1,519,402
Number of common stares received \| shares	149,645
Convertible Subordinated Notes Due 2023 \| Privately-negotiated capped call option
Debt disclosures
Payments for capped call options			$ 36,800
Number of derivative instruments purchased \| item			2	2
Strike price for the underlying number of shares (in dollars per share) \| $ / shares		$ 21.32	$ 27.79		$ 19.77
Cap price for the underlying number of shares (in dollars per share) \| $ / item		29.16	38.00	38.00	27.04
Convertible Subordinated Notes Due 2023 \| Stock prices below $27.79 per share \| Maximum
Debt disclosures
Net shares settlement payable to the entity \| shares			2,779,659
Convertible Subordinated Notes Due 2023 \| Stock prices below $27.79 per share \| Minimum
Debt disclosures
Net shares settlement payable to the entity \| shares			0
Convertible Subordinated Notes Due 2023 \| Stock prices above $38.00 per share
Debt disclosures
Incremental Common Shares Attributable to Capped Call Options \| shares			0
9% fixed rate term notes due 2029
Debt disclosures
Non-Recourse Notes Payable due 2029					$ 493,845				$ 493,162
9% fixed rate term notes due 2029 \| GSK
Debt disclosures
Loan amount										$ 450,000
Interest rate (as a percent)										9.00%
Interest amount added to principal balance					$ 700	$ 6,400	$ 43,800
9% fixed rate term notes due 2029 \| Future
Debt disclosures
Debt prepayment premium (as a percent)								2.50%

Shareholders' Deficit (Details) - October 2015 TO - Common Stock $ / shares in Units, $ in Millions	3 Months Ended
	Mar. 31, 2016 USD ($) $ / shares shares
Shareholders' Deficit
Number of shares purchased and retired \| shares	2,449,632
Average repurchase price per share, including associated fees and expenses \| $ / shares	$ 10.35
Share repurchase price \| $	$ 25.4

Commitments and Contingencies (Details) - Lease payments guarantee $ in Millions	Mar. 31, 2016 USD ($)
Operating Leases
Total lease payments	$ 26.2
Estimated fair value of the guarantee	$ 1.3

Income Taxes (Details)	3 Months Ended
Income Taxes (Details)	Mar. 31, 2016	Mar. 31, 2015
Income Taxes
Effective tax rate (as a percent)	0.15%	0.00%